TITLE

Inspections come under the microscope

AUTHOR(S)
Challener, Cynthia
PUB. DATE
January 2008
SOURCE
ICIS Chemical Business;1/28/2008, Vol. 273 Issue 4, p20
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the shortcomings of the U.S. Food and Drug Administration (FDA)'s overseas drug inspections. It mentions that active ingredients of over-the-counter medicines in the U.S. are produced in China and India and FDA inspects only a part of them. In a letter to the FDA, House Energy and Commerce Committee chairman John Dingell recommended that a permanent FDA office be established in each country.
ACCESSION #
31773629

 

Related Articles

  • Nonprescription Drug Safe Use Regulatory Expansion. Baker, Danial E. // Hospital Pharmacy;Jun2013, Vol. 48 Issue 6, p448 

    The author discusses some key questions about switching a prescription-only medication to over-the-counter status in the U.S. and a new law will see this change wherein over 90 ingredients, indications, or dosage strengths will acquire non-prescription status from prescription status. The...

  • Keryx's Zerenex Phase II Wows; Expanded CKD Sales in Reach? Osborne, Randy // BioWorld Today;11/6/2013, Vol. 24 Issue 214, p1 

    The article discusses Phase II trial by Keryx Biopharmaceuticals Inc. of ferric citrate Zerenex which may be poised to become the first oral iron booster that also provides phosphorus control in chronic kidney disease (CKD) patients. It states that the compound met both co-primary endpoint,...

  • FDA places hold on pivotal DOV Pharmaceutical anti-anxiety drug study.  // PharmaWatch: Biotechnology;November 2003, Vol. 2 Issue 11, p9 

    Reports on the suspension of the anti-anxiety drug clinical trial of DOV Pharmaceutical Inc. by the U.S. Food and Drug Administration. Request of the agency for additional safety data on the drug; Intention of the firm to gather the necessary information; Results of the phase II trial of ocinaplon.

  • Help FDA regulate OTC drugs. Ferreri, Stefanie // Pharmacy Today;Mar2013 OTC Supplement, p1 

    The author reflects on the regulation of over the counter (OTC) drugs by the U.S. Food and Drug Administration (FDA). The author highlights the significant role played by pharmacists in informing and advising the agency on the nonprescription products that are marketed in the U.S. Moreover, the...

  • Rapid HIV Testing at Home: Does It Solve a Problem or Create One? Walensky, Rochelle P.; Paltiel, A. David // Annals of Internal Medicine;9/19/2006, Vol. 145 Issue 6, p459 

    The U.S. Food and Drug Administration (FDA) is considering approval of an over-the-counter, rapid HIV test for home use. To date, testimony presented before the FDA has been overwhelmingly supportive. Advocates have argued enthusiastically that there is value in empowering individuals to manage...

  • As Use of Foreign Drug Trials Grows, FDA Oversight May Not Be Keeping Up. Mitka, Mike // JAMA: Journal of the American Medical Association;8/25/2010, Vol. 304 Issue 8, p843 

    The article examines the implication of the increasing reliance on foreign clinical trials for testing new drugs for the ability of the U.S. Food and Drug Administration (FDA) to monitor such research. According to a report issued by the U.S. Department of Health and Human Services' Office of...

  • FDA Urged to Make Application Data Public.  // BioWorld Today;6/29/2009, Vol. 20 Issue 123, p4 

    This article reports on the recommendation from the Pew Prescription Project about the release of product safety and efficacy information by the U.S. Food & Drug Administration (FDA). Allan Coukell, director of the project, is encouraging the FDA to release information to the public without...

  • The dilemma lurking over the counter. FOXHALL, KATHRYN // Contemporary Pediatrics;Nov2008, Vol. 25 Issue 11, p25 

    The author addresses the safety issue of over-the-counter (OTC) cough and cold medications being sold in the U.S. Research published in a 2008 issue of "Pediatrics" estimated that 7,091 children under age 12 are treated in emergency rooms for adverse events related to these medications. Given...

  • New Rules Increase the Safety of OTC Ingredients.  // FDA Consumer;Jul/Aug2004, Vol. 38 Issue 4, p2 

    Reports on the rules published by the U.S. Food and Drug Administration to enhance the safe use of over-the-counter drug products. Effectivity of the rules; Products covered in the regulation; Details of the rules.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics